Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide added to melphalan and prednisone in elderly patients with previously untreated multiple myeloma
NL-OMON25578Phase 3Active, not recruiting
- Sponsor
- HOVON
- Start
- Aug 2002
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Melphalan + Prednisone with Melphalan + Prednisone + Thalidomide (2 arms). Primary endpoints: Event-free survival and Response rate. Started Aug 2002; status: active, not recruiting.
02
Drugs
thalidomidemelphalanprednisone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON25578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25578.